Viagene
Executive Summary
Has filed for initial public offering of 2.5 mil. shares of stock at an anticipated offering price of $11 to $13 per share, the firm says Jan. 26. Poceeds will fund the San Diego firm's R&D of gene transfer drugs for viral infections, cancers and other diseases. First Boston, Prudential Securities and Nomura Securities are underwriters.